Crucial coronavirus vaccine data expected from Pfizer this week now appears unlikely to come before the U.S. election on Nov. 3.
On a call with investors Tuesday, Pfizer CEO Albert Bourla said that the company doesn't expect to make any announcement on its trial until about a week after the data and safety monitoring board conducts its review of the company's phase three vaccine trial. The board, which will assess whether its trial with German drugmaker BioNTech has been successful, has not conducted an interim efficacy analysis yet, Pfizer said.
"In case of a conclusive readout ... we will inform the public as soon as we complete the necessary administrative work, which we estimate to be completed within one week from the time we know," Bourla said on the call.
"Let's all have patience," he added. "I know how much the stress levels are growing. I know how much the vaccine is needed for the world."
The phase three trials are a critical last step needed to get the vaccines cleared for distribution. Three other U.S.-backed candidates are in phase three: Moderna, AstraZeneca and Johnson & Johnson. Pfizer expects to apply for an emergency use authorization with the Food and Drug Administration next month.
The board will not conduct its analysis until after there are 32 cases of Covid-19 diagnosed in Pfizer's phase three trial. The board could recommend ending the trial if the vaccine is found to be at least 77% effective, which means it could reduce the risk of getting Covid by 77%.
Since early September, Bourla has repeatedly said the company could have late-stage vaccine trial data as early as October. The timeline drew concerns and skepticism from infectious disease experts and scientists who also feared the process could be influenced by politics, not science. President Donald Trump has insisted a Covid-19 vaccine could be ready before Election Day.
Earlier in the day, Pfizer said it had enrolled more than 42,000 volunteers in its late-stage trial. It said nearly 36,000 of the volunteers have already received the second of its two-dose Covid-19 vaccine. In September, Pfizer expanded the enrollment of its phase three trial to up to 44,000 volunteers from the initial target of up to 30,000.
The vaccine contains genetic material called messenger RNA, or mRNA, which scientists hope provokes the immune system to fight the virus.
This is breaking news. Please check back for updates.
"come" - Google News
October 27, 2020 at 09:56PM
https://ift.tt/2Tqz6Uh
Crucial Covid vaccine data expected from Pfizer this week now unlikely to come before U.S. election - CNBC
"come" - Google News
https://ift.tt/2S8UtrZ
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update
Bagikan Berita Ini
0 Response to "Crucial Covid vaccine data expected from Pfizer this week now unlikely to come before U.S. election - CNBC"
Post a Comment